专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012168182A3 STRIKING PIN SAFETY ELEMENT 审中-公开
标题翻译：撞针保险
公开(公告)号：WO2012168182A3
公开(公告)日：2013-02-21
申请号：PCT/EP2012060495
申请日：2012-06-04
申请人： RHEINMETALL AIR DEFENCE AG , BRUNNER DOMINIC , GERBER MICHAEL , WIDMER ROMAN
发明人： BRUNNER DOMINIC , GERBER MICHAEL , WIDMER ROMAN
IPC分类号： F41A17/06 , F41A17/64
CPC分类号： F41A17/063 , F41A17/06 , F41A17/64
摘要： The invention relates to a striking pin safety element (1) that can be remotely operated. In this connection, a further electrically remotely operated safety device (3) is added to the mechanical striking pin safety element (2), the principle being that the discharge of a shot is possible only if the striking pin (12) has been released both locally mechanically and electrically via the remote operation. As an electric striking pin safety element (3), an electric actuator (18) is incorporated into the mechanical striking pin safety element (2).
摘要翻译：公开了一种遥控的撞针安全（1）。在此，机械撞针安全（2）加入到另外的电遥控锁定装置（3），其中，所述基本原则是，击发只可能当撞针（12）解锁时，在本地机械和电与远程控制。电气撞针安全（3）被嵌入，在机械撞针安全性的电致动器（18）（2）。

2. 发明申请

WO2009026517A3 THERAPY FOR COMPLICATIONS OF DIABETES 审中-公开
公开(公告)号：WO2009026517A3
公开(公告)日：2009-02-26
申请号：PCT/US2008/074013
申请日：2008-08-22
申请人： GILEAD COLORADO, INC. , RODEN, Robert, L. , GORCZYNSKI, Richard, J. , GERBER, Michael, J.
发明人： RODEN, Robert, L. , GORCZYNSKI, Richard, J. , GERBER, Michael, J.
IPC分类号： A61K31/505 , A61P13/12
摘要： A selective ET A receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome is disclosed. A selective ET A receptor antagonist for use in treating a complex of comorbidities in an elderly diabetic human subject, wherein the selective ET A receptor antagonist is for administration in combination or as adjunctive therapy with (a) at least one additional agent that is (i) other than a selective ET A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension, and optionally (b) at least one antihypertensive other than a selective ET A receptor antagonist is disclosed. Further, a therapeutic combination comprising a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET A receptor antagonist is disclosed.

3. 发明申请

WO2009026517A2 THERAPY FOR COMPLICATIONS OF DIABETES 审中-公开
标题翻译：治疗糖尿病的药物
公开(公告)号：WO2009026517A2
公开(公告)日：2009-02-26
申请号：PCT/US2008074013
申请日：2008-08-22
申请人： GILEAD COLORADO INC , RODEN ROBERT L , GORCZYNSKI RICHARD J , GERBER MICHAEL J
发明人： RODEN ROBERT L , GORCZYNSKI RICHARD J , GERBER MICHAEL J
IPC分类号： A61K31/505 , A61P13/12
CPC分类号： A61K31/505 , A61K9/0053 , A61K31/4025 , A61K31/549 , A61K45/06
摘要： A selective ETA receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome is disclosed. A selective ETA receptor antagonist for use in treating a complex of comorbidities in an elderly diabetic human subject, wherein the selective ETA receptor antagonist is for administration in combination or as adjunctive therapy with (a) at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension, and optionally (b) at least one antihypertensive other than a selective ETA receptor antagonist is disclosed. Further, a therapeutic combination comprising a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist is disclosed.
摘要翻译：公开了用于增加糖尿病性肾病和/或代谢综合征的人类受试者血糖控制和/或胰岛素敏感性的方法中的选择性ETA受体拮抗剂。一种选择性ETA受体拮抗剂，其用于治疗老年糖尿病人受试者的合并症复合物，其中所述选择性ETA受体拮抗剂用于联合给药或作为辅助治疗，与（a）至少一种另外的药剂是（i）其它公开了选择性ETA受体拮抗剂和（ii）有效治疗糖尿病和/或除了高血压之外的所述合并症中的至少一种，以及任选地（b）除了选择性ETA受体拮抗剂之外的至少一种抗高血压药。此外，公开了包含选择性ETA受体拮抗剂和除选择性ETA受体拮抗剂之外的至少一种抗糖尿病，抗肥胖症或抗脂肪代谢剂的治疗组合。

4. 发明申请

WO2008060890A3 DARUSENTAN ORAL DOSAGE FORM 审中-公开
标题翻译： DARUSENTAN口服剂型
公开(公告)号：WO2008060890A3
公开(公告)日：2009-01-15
申请号：PCT/US2007083701
申请日：2007-11-06
申请人： GILEAD COLORADO INC , GERBER MICHAEL J , GORCZYNSKI RICHARD J , RODEN ROBERT L , SHAH PRAFUL K
发明人： GERBER MICHAEL J , GORCZYNSKI RICHARD J , RODEN ROBERT L , SHAH PRAFUL K
IPC分类号： A61K9/20 , A61K31/505
CPC分类号： A61K31/505 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2813 , A61K9/2853 , A61K9/2866
摘要： A solid discrete orally deliverable pharmaceutical dosage form comprises darusentan and one or more pharmaceutically acceptable excipients; wherein (a) the darusentan is in solid particulate form having a mean particle size of about 5 to about 200 µm and is present in the dosage form in an amount of about 1 to about 600 mg; and (b) the dosage form exhibits at least about 90% dissolution of the darusentan in 30 minutes in a standard in vitro dissolution test. A method for lowering blood pressure, for example in a patient having resistant hypertension, comprises administering such a dosage form once daily to the patient.
摘要翻译：固体分散的口服递送药物剂型包含darusentan和一种或多种药学上可接受的赋形剂; 其中（a）所述darusentan是具有约5至约200μm的平均粒度的固体颗粒形式，并且在剂型中以约1至约600mg的量存在; 和（b）在标准体外溶出试验中，剂型在30分钟内显示至少约90％的darusentan溶解。一种降低血压的方法，例如在具有耐药性高血压的患者中，包括每天向患者施用这种剂型。

5. 发明申请

WO2007098390A3 METHOD FOR TREATING RESISTANT HYPERTENSION 审中-公开
标题翻译：治疗抗高血压的方法
公开(公告)号：WO2007098390A3
公开(公告)日：2007-11-15
申请号：PCT/US2007062291
申请日：2007-02-16
申请人： GILEAD COLORADO INC , GERBER MICHAEL J , GORCZYNSKI RICHARD J , RODEN ROBERT L
发明人： GERBER MICHAEL J , GORCZYNSKI RICHARD J , RODEN ROBERT L
IPC分类号： A61K31/435 , A61P9/12
CPC分类号： A61K31/401 , A61K31/4184 , A61K31/455 , A61K31/505 , A61K31/549 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： A new use of darusentan is provided in preparation of a pharmaceutical composition, for adjunctive administration with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers, to lower blood pressure in a patient having resistant hypertension; wherein the composition is orally deliverable and comprises darusentan in a daily dose effective, in combination with said regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.
摘要翻译：在制备药物组合物中提供了darusentan的新用途，用于用基线抗高血压药物方案辅助施用，该方法包括施用至少一种利尿剂和至少两种选自以下至少两种的抗高血压药物：（a）ACE抑制剂和血管紧张素II （b）β-肾上腺素受体阻断剂和（c）钙通道阻断剂，以降低患有顽固性高血压的患者的血压; 其中所述组合物是口服递送的并且包含与所述方案组合有效的每日剂量的达卢生坦，以在选自以下的一个或多个血压参数中提供至少约3mmHg的降低：坐位收缩期，坐位舒张期，小时动态收缩压，24小时动态舒张压，最大昼夜收缩压和最大昼夜舒张压。

6. 发明申请

WO2007098390A2 METHOD FOR TREATING RESISTANT HYPERTENSION 审中-公开
标题翻译：治疗抗高血压的方法
公开(公告)号：WO2007098390A2
公开(公告)日：2007-08-30
申请号：PCT/US2007/062291
申请日：2007-02-16
申请人： GILEAD COLORADO, INC. , GERBER, Michael, J. , GORCZYNSKI, Richard, J. , RODEN, Robert, L.
发明人： GERBER, Michael, J. , GORCZYNSKI, Richard, J. , RODEN, Robert, L.
IPC分类号： A61K31/505 , A61K45/06 , A61P9/12
CPC分类号： A61K31/401 , A61K31/4184 , A61K31/455 , A61K31/505 , A61K31/549 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： A new use of darusentan is provided in preparation of a pharmaceutical composition, for adjunctive administration with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers, to lower blood pressure in a patient having resistant hypertension; wherein the composition is orally deliverable and comprises darusentan in a daily dose effective, in combination with said regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.
摘要翻译：提供了用于制备药物组合物的新用途，用于使用基线抗高血压方案进行辅助给药，其包括施用至少一种利尿剂和至少两种抗高血压药物，所述药物选自（a）ACE抑制剂和血管紧张素II 受体阻断剂，（b）β-肾上腺素能受体阻断剂和（c）钙通道阻滞剂，以降低患有耐药性高血压的患者的血压; 其中所述组合物是口服递送的，并且包含与所述方案组合的日剂量有效的达赖生坦，以在一个或多个血压参数中提供至少约3mmHg的减少，所述一个或多个血压参数选自从坐位收缩期，放置舒适期，小时动态收缩期，24小时动态舒张期，最大昼间收缩期和最大昼夜舒张压。

7. 发明申请

WO2007098387A2 ANTIHYPERTENSIVE THERAPY 审中-公开
标题翻译：抗高血压治疗
公开(公告)号：WO2007098387A2
公开(公告)日：2007-08-30
申请号：PCT/US2007/062288
申请日：2007-02-16
申请人： GILEAD COLORADO, INC. , GERBER, Michael, J. , GORCZYNSKI, Richard, J. , RODEN, Robert, L.
发明人： GERBER, Michael, J. , GORCZYNSKI, Richard, J. , RODEN, Robert, L.
IPC分类号： A61P9/12
CPC分类号： A61K31/435
摘要： A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.
摘要翻译：提供了达卢生坦的新用途，用于制备用于降低患有对一种或多种药物的基线抗高血压治疗抗性的患者的血压降低的药物组合物。该组合物包含提供治疗有效日剂量的达卢生坦; （a）所述组合物可口服递送和/或（b）达卢生坦的日剂量有效提供至少约3mmHg的降低，所述一个或多个血压参数选自坐位收缩期，坐位舒张期槽，24 - 小时动态收缩压，24小时动态舒张压，最大昼夜收缩压和最大昼夜舒张压。还提供了darusentan在制备用于降低对基线抗高血压治疗具有抗性的患者的血压降低的药物组合物中的新用途，其中该组合物与至少一种利尿剂和至少一种选自ACE抑制剂的抗高血压药物，血管紧张素II受体阻滞剂，β-肾上腺素受体阻滞剂和钙通道阻滞剂。

8. 发明申请

WO2008140808A1 METHODS FOR ADMINISTRATION OF RADIOTHERAPEUTIC AGENTS 审中-公开
标题翻译：放射治疗药物的管理方法
公开(公告)号：WO2008140808A1
公开(公告)日：2008-11-20
申请号：PCT/US2008/006040
申请日：2008-05-09
申请人： PEAK BIOSCIENCES, INC. , GERBER, Michael, J. , WARREN, Stephen, L. , MATSUURA, James, E.
发明人： GERBER, Michael, J. , WARREN, Stephen, L. , MATSUURA, James, E.
IPC分类号： A01N43/42
CPC分类号： A61K31/00 , A61K38/1703 , A61K38/18 , A61K38/1866 , A61K38/195 , A61K38/20 , A61K38/22 , A61K45/06 , A61K48/00 , A61K51/0491 , A61K2300/00
摘要： A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent. Thus, not only does the combination effectively kill the transit amplifying cell population, the most rapidly replicating type of cell in a tumor, but it also effectively kills the tumor stem cells, which give rise to the transit amplifying cells, for a longer lasting anticancer effect.
摘要翻译：提供了用于治疗涉及过度增殖细胞例如恶性肿瘤，晚期实体瘤如多形性成胶质细胞瘤的病症和非恶性过度增殖病理状况如成人黄斑变性的病症的方法。任选地在空间上限定的组织体内施用短程，非选择性细胞杀伤放射治疗物质，任选与刺激或诱导DNA生物合成的促有丝分裂剂组合。以这种方式，放射治疗剂易于杀死的过度增殖的百分比增加。可以诱导癌干细胞与促有丝分裂剂进入S期，然后用放射治疗剂杀死。因此，不仅组合有效地杀死了肿瘤中最快速复制型细胞的转运扩增细胞群，而且还有效地杀死了产生转运扩增细胞的肿瘤干细胞，以达到更持久的抗癌作用影响。

9. 发明申请

WO2005092333A1 (R)-ENOXIMONE SULFOXIDE AND ITS USE IN THE TREATMENT OF PDE-III MEDIATED DISEASES 审中-公开
标题翻译：（R）-ENOXIMONE SULFOXIDE及其在治疗PDE-III介导的疾病中的应用
公开(公告)号：WO2005092333A1
公开(公告)日：2005-10-06
申请号：PCT/US2005/009632
申请日：2005-03-22
申请人： MYOGEN, INC. , BRISTOW, Michael, R. , GERBER, Michael, J. , GORCZYNSKI, Richard, J.
发明人： BRISTOW, Michael, R. , GERBER, Michael, J. , GORCZYNSKI, Richard, J.
IPC分类号： A61K31/4166
CPC分类号： C07D233/70
摘要： The present invention provides the (R)-(+) enoximone sulfoxide enantiomer, as well as pharmaceutical formulations of the purified (R)-(+) sulfoxide enantiomer. Also provided are methods of treating diseases in which inhibition of PDE-III may be beneficial.
摘要翻译：本发明提供了（R） - （+）烯氧基亚砜对映异构体，以及纯化的（R） - （+）亚砜对映异构体的药物制剂。还提供了治疗其中抑制PDE-III可能是有益的疾病的方法。

10. 发明申请

WO9505167A3 TREATMENT OF ADVERSE EFFECTS ASSOCIATED WITH ADMINISTRATION OF EXTRACELLULAR HEMOGLOBIN 审中-公开
标题翻译：治疗与细胞外HEMOGLOBIN的管理有关的不良反应
公开(公告)号：WO9505167A3
公开(公告)日：1995-04-13
申请号：PCT/IB9400239
申请日：1994-08-09
申请人： SOMATOGEN INC , GERBER MICHAEL J
发明人： GERBER MICHAEL J
IPC分类号： A61K45/00 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4422 , A61K38/42 , A61K45/06 , A61P43/00
CPC分类号： A61K45/06 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4422 , A61K38/42 , Y10S514/815 , A61K2300/00
摘要： The present invention relates to the use of extracellular hemoglobin for the preparation of a medicament for use in the treatment of various disorders or in association with other therapies.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式